MUC1, a molecule aberrantly glycosylated and overexpressed in a variety of epithelial cancers [20], was one of the first TAAs to be tested in a clinical trial of therapeutic cancer vaccines in patients with metastatic colon, pancreatic, and breast cancer [1]. Here, MUC1 is linked to breast carcinoma.